Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers

International Journal of Cancer

Volumn 138, Issue 5, 2016, Pages 1139-1145

  De Cuba, E M V ^a   Snaebjornsson, P ^a,b   Heideman, D A M ^a   Van Grieken, N C T ^a   Bosch, L J W ^a,b   Fijneman, R J A ^a,b   Belt, E ^c   Bril, H ^d   Stockmann, H B A C ^d   Hooijberg, E ^a   Punt, C J A ^e   Koopman, M ^f   Nagtegaal, I D ^g   Coupe V H M ^a   Carvalho, B ^a,b   Meijer, G A ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Department of Orthopaedic Surgery   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRAF; colon cancer; KRAS; microsatellite instability; survival

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; COLON TUMOR; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84955671066     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29855     Document Type: Article

References (35)

1. Sinicrope FA, Sargent DJ., Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012; 18: 1506-12.
2. Phipps AI, Buchanan DD, Makar KW, et al., BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012; 21: 1792-8.
3. Parsons MT, Buchanan DD, Thompson B, et al., Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012; 49: 151-7.
4. Nash GM, Gimbel M, Cohen AM, et al., KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 2010; 17: 416-24.
5. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al., The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-402.
6. Roth AD, Tejpar S, Delorenzi M, et al., Prognostic Role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
7. Oliveira C., Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-11.
8. Sahin IH, Kazmi SMA, Yorio JT, et al., Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature. J Cancer 2013; 4: 320-2.
9. Merok MA, Ahlquist T, Royrvik EC, et al., Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 2013; 24: 1274-82.
10. Sargent DJ, Shi Q, Yothers G, et al., Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J Clin Oncol [Abstract] 2014; 32: 3507.
11. Sinicrope FA, Mahoney MR, Smyrk TC, et al., Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013; 31: 3664-72.
12. Klingbiel D, Saridaki Z, Roth AD, et al., Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 2015; 26: 126-32.
13. Tran B, Kopetz S, Tie J, et al., Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32.
14. Venderbosch S, Nagtegaal ID, Maughan TS, et al., Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20: 5322-30.
15. Hoffmeister M, Blaker H, Kloor M, et al., Body mass index and microsatellite instability in colorectal cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 2013; 22: 2303-11.
16. Thiel A, Ristimäki A., Toward a molecular classification of colorectal cancer: the role of BRAF. Front Oncol 2013; 3: 281.
17. Lee D-W, Kim KJ, Han S-W, et al., KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol 2015; 22: 187-94.
18. Belt EJT, Velde te EA, Krijgsman O, et al., High lymph node yield is related to microsatellite instability in colon cancer. Ann Surg Oncol 2012; 19: 1222-30.
19. de Weger VA, Turksma AW, Voorham QJM, et al., Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res 2012; 18: 882-9.
20. Dutch Federation of Biomedical Scientific Societies. Code for proper secondary use of human tissue in the Netherlands. Available at: http://www.federa.org /[cited 2014 Dec 23].
21. Heideman DAM, Lurkin I, Doeleman M, et al., KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed paraffin-embedded tumor-derived DNA. J Mol Diagn 2012; 14: 247-55.
22. French AJ, Sargent DJ, Burgart LJ, et al., Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14: 3408-15.
23. Gavin PG, Colangelo LH, Fumagalli D, et al., Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18: 6531-41.
24. Hutchins G, Southward K, Handley K, et al., Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.
25. Ogino S, Shima K, Meyerhardt JA, et al., Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012; 18: 890-900.
26. Lin C-C, Lin J-K, Lin T-C, et al., The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J Surg Oncol 2014; 110: 451-7.
27. Maestro ML, Vidaurreta M, Sanz-Casla MT, et al., Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. Ann Surg Oncol 2007; 14: 1229-36.
28. Shaukat A, Arain M, Thaygarajan B, et al., Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci 2010; 55: 2352-6.
29. Kalady MF, DeJulius KL, Sanchez JA, et al., BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 2012; 55: 128-33.
30. Samowitz WS, Sweeney C, Herrick J, et al., Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-9.
31. Lochhead P, Kuchiba A, Imamura Y, et al., Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105: 1151-6.
32. Eklöf V, Wikberg ML, Edin S, et al., The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 2013; 108: 2153-63.
33. Luey N, Toon CW, Sioson L, et al., A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma. PLoS ONE 2014; 9: e106105.
34. Goldstein J, Tran B, Ensor J, et al., Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 2014; 25: 1032-8.
35. Compton CC, Fielding LP, Burgart LJ, et al., Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-94.